About dabrafenib mesilate
BRAF kinase inhibitor
Used for
- Treats BRAF V600 mutation-positive melanoma, alone or with trametinib.
- Treats certain BRAF V600 mutation-positive thyroid and lung cancers with trametinib.
Usual adult dose
150 mg by mouth twice daily, usually with trametinib; dosing may vary by cancer and combination.
Usual dose in children
For selected children with BRAF V600E low-grade glioma: 2.25 mg/kg twice daily under specialist supervision; maximum 150 mg twice daily.
Common side effects
- Fever and chills
- Rash and other skin reactions
- Headache, fatigue, or joint pain
- Nausea, vomiting, or diarrhea
Important warnings
- Can cause serious fever, sometimes with dehydration or low blood pressure.
- May cause new skin cancers; skin checks are needed during treatment.
- Can cause bleeding, eye problems, or heart problems, especially with trametinib.
- May harm an unborn baby; effective contraception is required during treatment.
Pregnancy
May cause fetal harm. Avoid pregnancy during treatment and for two weeks after the last dose.
Breastfeeding
Do not breastfeed during treatment and for two weeks after the last dose.
Interactions
- Strong CYP3A4 or CYP2C8 inhibitors may increase dabrafenib exposure.
- Strong CYP3A4 or CYP2C8 inducers may reduce effectiveness.
- Dabrafenib can reduce hormonal contraceptive effectiveness; use non-hormonal contraception.
- May reduce levels of warfarin and other medicines metabolized by CYP enzymes.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.